Trial Profile
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Vitespen (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms HeatShock
- 02 Jun 2015 Results on response to therapy and gene expression presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 01 Jun 2015 Data was presented in 2015 ASCO Annual Meeting, per Agenus media release.
- 01 Jun 2015 Results published in the Agenus Media Release.